AnteoTech Limited

Equities

ADO

AU000000ADO8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:40:06 16/07/2024 am IST			5-day change	1st Jan Change
0.021 ^AUD	-4.55%		0.00%	-41.67%

14/05	AnteoTech Completes AU$1.4 Million Share Purchase Plan	MT
02/05	AnteoTech Extends Closing Date of Share Purchase Plan	MT

Anteo Diagnostics : Reinstatement to Official Quotation

January 06, 2016 at 06:05 am IST

Letter to

MARKET RELEASE

6 January 2016

Anteo Diagnostics Limited

REINSTATEMENT TO OFFICIAL QUOTATION

The suspension of trading in the securities of Anteo Diagnostics Limited (the "Company") will be lifted immediately, following receipt of an announcement regarding revised terms in relation to the acquisition of DIAsource ImmunoAssays S.A by the Company.

Security Code:

ADO

Elvis Onyura

Senior Adviser, Listings Compliance (Sydney)

ASX Compliance Pty Limited

ABN 26 087 780 489

20 Bridge Street

Sydney NSW 2000

www.asx.com.au Customer service 13 12 79

Anteo Diagnostics Limited issued this content on 2016-01-05 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-06 00:34:04 UTC

Original Document: https://wcsecure.weblink.com.au/clients/anteodx/headline.aspx?headlineid=2900857

Latest news about AnteoTech Limited

AnteoTech Completes AU$1.4 Million Share Purchase Plan	14/05	MT
AnteoTech Extends Closing Date of Share Purchase Plan	02/05	MT
Anteotech Seeks to Raise AU$6 Million From Share Placement; Shares Fall 26%	08/04	MT
AnteoTech Receives AU$1.39 Million from Queensland Critical Minerals and Battery Technology Fund; Shares Down 3%	27/03	MT
AnteoTech Settles Patent Claims for AU$300,000	04/03	MT
AnteoTech Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02	CI
Anteotech Completes Construction of Anteo X Production Facility in Brisbane; Shares Climb 6%	15/02	MT
AnteoTech Produces Anode Material Containing Proprietary Technology	07/12	MT
AnteoTech Receives AU$3.8 Million R&D Tax Rebate; Shares Rise 3%	12/23/12	MT
AnteoTech Limited(ASX:ADO) dropped from S&P Global BMI Index	18/23/18	CI
AnteoTech Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
AnteoTech Limited Announces Appointment of Mr. Andrew Cook as Company Secretary, Effective from 28 August 2023	22/23/22	CI
Anteotech Limited Announces Appointment of Mr. Andrew Cook as Chief Financial Officer	22/23/22	CI
AnteoTech Halts Trade	24/23/24	MT
AnteoTech Limited Announces Retirement of Christopher Parker from the Board of Directors	27/23/27	CI
Anteotech to Undergo Major Rebranding; Shares Jump 10%	23/23/23	MT
Anteotech Limited Announces Changes to Leadership Team	01/23/01	CI
Anteotech Limited Announces Changes to Leadership Team	01/23/01	CI
AnteoTech Limited(ASX:ADO) dropped from S&P/ASX Emerging Companies Index	20/23/20	CI
AnteoTech Limited(ASX:ADO) dropped from S&P/ASX All Ordinaries Index	20/23/20	CI
Anteotech, Wyon to Collaborate on Silicon Anodes for Micro-Batteries	02/23/02	MT
Anteotech, Trinseo Europe Sign Deal to Develop New Product	22/23/22	MT
AnteoTech Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/23/22	CI
AnteoTech Appoints Chief Marketing Officer	15/23/15	MT
AnteoTech Limited Appoints Tsui Min Lian as Chief Marketing Officer, Effective 15 March 2023	15/23/15	CI

Chart AnteoTech Limited

Duration

Period

More charts

Company Profile

AnteoTech Limited is an Australia-based company engaged in providing solutions for the clean energy and life sciences markets using applied materials technology. The principal activities of the Company consist of development and commercialization of nanotechnologies with surface management applications. The Companyâs lead product, Anteo X, provides significant improvement in anode performance and the Company partners with global suppliers in lithium-ion battery manufacturing. Its clean energy technology (CET) technologies improve the energy densities, cycle life and cost- effectiveness of lithium-ion batteries. The Company has two programs underway: Anteo X, its binder additive and the High Silicon Anode technology. The Life Sciences division services the point-of-care and in vitro diagnostics markets from global diagnostics companies to technology developers. Its AnteoBind provides advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ANTEOTECH LIMITED	-41.67%	3.68Cr
MODERNA, INC.	+22.15%	4.66TCr
LONZA GROUP AG	+44.59%	4.17TCr
IQVIA HOLDINGS INC.	-2.37%	4.12TCr
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	3.24TCr
ICON PUBLIC LIMITED COMPANY	+20.42%	2.82TCr
CELLTRION, INC.	-6.35%	2.81TCr
UNITED THERAPEUTICS CORPORATION	+48.83%	1.45TCr
MEDPACE HOLDINGS, INC.	+45.00%	1.37TCr
BIO-TECHNE CORPORATION	+0.06%	1.22TCr

Other Biotechnology & Medical Research